🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

187 results for “Roche” Clear

  1. IMFINZI 50 mg/mL concentrate for solution for infusion., Tiragolumab, IMFINZI 50 mg/mL concentrate for solution for infusion., Tecentriq 840 mg concentrate for solution for infusion

    Roche Registration Limited

    Non−small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  2. INAVOLISIB, PALBOCICLIB, Faslodex 250 mg solution for injection., INAVOLISIB, PALBOCICLIB, INAVOLISIB, PALBOCICLIB, INAVOLISIB

    Roche Registration Limited

    HR+/HER2-Negative Locally Advanced or Metastatic Breast cancer with PIK3CA mutation

    phase 3 small molecule active

    1 trial

  3. LETROZOLE, PALBOCICLIB, Inavolisib placebo, LETROZOLE ACCORD HEALTHCARE 2,5 mg, comprimé pelliculé, IBRANCE 75 mg film-coated tablets, IBRANCE 125 mg film-coated tablets, Letrozol STADA® 2,5 mg Filmtabletten, INAVOLISIB, IBRANCE 100 mg film-coated tablets, INAVOLISIB, RIBOCICLIB, PALBOCICLIB, RIBOCICLIB, PALBOCICLIB

    Roche Registration Limited

    Endocrine-Sensitive phosphatidylinositol 3-kinase (PIK3CA)-Mutated, Hormone Receptor-Positive, human epidermal growth factor receptor 2- (HER2-) negative advanced breast cancer

    phase 3 small molecule active

    1 trial

  4. Lucentis 10 mg/ml solution for injection, FARICIMAB

    Roche Registration Limited

    Choroidal neovascularization secondary to pathologic myopia

    phase 3 small molecule active

    1 trial

  5. METHYLPREDNISOLONE , PREDNISONE , Gazyvaro 1,000 mg concentrate for solution for infusion., Obinutuzumab placebo, Myfenax 500 mg film-coated tablets, DIPHENHYDRAMINE , PARACETAMOL

    Roche Registration Limited

    Lupus Nephritis (LN)

    phase 3 small molecule active

    1 trial

  6. MabThera 500 mg concentrate for solution for infusion, Gazyvaro 1,000 mg concentrate for solution for infusion., Glofitamab, RoActemra 20 mg/mL concentrate for solution for infusion

    Roche Registration Limited

    Relapsed or refractory diffuse large B-cell lymphoma

    phase 3 small molecule active

    1 trial

  7. MabThera 500 mg concentrate for solution for infusion, Polivy 140 mg powder for concentrate for solution for infusion., GEMCITABINE , OXALIPLATIN

    Roche Registration Limited

    Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  8. Methylprednisolon acis 250 mg Pulver und Lösungsmittel zur Herstellung einer Injektions- bzw. Infusionslösung, Ocrevus 300 mg concentrate for solution for infusion, Gilenya 0.25 mg hard capsules, Placebo for FINGOLIMOD, Placebo for Ocrelizumab, Gilenya 0.25 mg hard capsules, Reisetabletten AL Dimenhydrinat 50 mg pro Tablette, Methylprednisolon acis 1000 mg Pulver und Lösungsmittel zur Herstellung einer Injektions- bzw. Infusionslösung, Gilenya 0.5 mg hard capsules, Gilenya 0.25 mg hard capsules

    Roche Registration Limited

    Relapsing-Remitting Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  9. Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Ocrevus 300 mg concentrate for solution for infusion, Ocrevus 300 mg concentrate for solution for infusion, Paracetamol Accord 1000 mg comprimate efervescente, Diphenhydramine Hydrochloride Tablets 50 mg

    Roche Registration Limited

    Progressive multiple sclerosis (PMS)

    phase 3 small molecule active

    1 trial

  10. Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Ocrevus 300 mg concentrate for solution for infusion, Paracetamol Accord 1000 mg comprimate efervescente, Ocrevus 300 mg concentrate for solution for infusion, Diphenhydramine Hydrochloride Tablets 50 mg

    Roche Registration Limited

    Multiple sclerosis (MS)

    phase 3 small molecule active

    1 trial

  11. Mosunetuzumab, Mosunetuzumab

    Roche Registration Limited

    NA

    phase 3 small molecule active

    1 trial

  12. NovoSeven 8 mg (400 KIU) powder and solvent for solution for injection, Voncento 250 IU FVIII / 600 IU VWF (5 ml solvent) powder and solvent for solution for injection/infusion, ADVATE 1 500 IU/2 ml powder and solvent for solution for injection, Voncento 500 IU FVIII / 1200 IU VWF (5 ml solvent) powder and solvent for solution for injection/infusion, ELOCTA 500 IU Powder and solvent for solution for injection, ELOCTA 750 IU Powder and solvent for solution for injection, ELOCTA 2000 IU Powder and solvent for

    Roche Registration Limited

    Type 3 Von Willebrand Disease

    phase 3 small molecule active

    1 trial

  13. Ocrelizumab, -, METHYLPREDNISOLONE , DEXAMETHASONE , Ocrevus, -

    Roche Registration Limited

    Neurological Disease

    phase 3 small molecule active

    1 trial

  14. Ocrevus 300 mg concentrate for solution for infusion

    Roche Registration Limited

    Multiple Sclerosis (MS)

    phase 3 small molecule active

    1 trial

  15. Ocrevus 300 mg concentrate for solution for infusion, Ocrevus 920 mg solution for injection

    Roche Registration Limited

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  16. Ocrevus 300 mg concentrate for solution for infusion, Paracetamol 500mg Tablets, Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Placebo ocrelizumab, Diphenhydramine Hydrochloride Tablets 50 mg, Ocrevus 300 mg concentrate for solution for infusion

    Roche Registration Limited

    Relapsing Multiple Sclerosis (MS)

    phase 3 small molecule active

    1 trial

  17. Ocrevus, Ocrevus 300 mg concentrate for solution for infusion

    Roche Registration Limited

    Multiple Sclerosis (MS)

    phase 3 small molecule active

    1 trial

  18. Phase III Randomized, Open-Label, Multicenter Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination with Lenalidomide in Comparison to Rituximab in Combination with Lenalidomide with a Non-Randomized, Single Arm US Extension of Mosunetuzumab in Combination with Lenalidomide in Patients with Follicular Lymphoma After at Least One Line of Systemic Therapy

    Roche Registration Limited

    Relapsed/refractory follicular lymphoma

    phase 3 other active

    1 trial

  19. Phesgo 1200 mg/600 mg solution for injection, Perjeta 420 mg concentrate for solution for infusion, Herceptin 600 mg solution for injection in vial, Phesgo 600 mg/600 mg solution for injection, Herceptin 150 mg powder for concentrate for solution for infusion

    Roche Registration Limited

    HER2-POSITIVE EARLY BREAST CANCER

    phase 3 small molecule active

    1 trial

  20. Phesgo 600 mg/600 mg solution for injection, Herceptin 600 mg solution for injection in vial, Perjeta 420 mg concentrate for solution for infusion, Phesgo 1200 mg/600 mg solution for injection, Kadcyla 160 mg powder for concentrate for solution for infusion.

    Roche Registration Limited

    Early or Locally Advanced/ Inflammatory HER2-Positive Breast Cancer

    phase 3 small molecule active

    1 trial

  21. Placebo Ocrelizumab, Paracetamol 500mg Tablets, Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Ocrevus 300 mg concentrate for solution for infusion, Ocrevus 300 mg concentrate for solution for infusion, Diphenhydramine Hydrochloride Tablets 50 mg

    Roche Registration Limited

    Primary Progressive Multiple Sclerosis (PPMS)

    phase 3 small molecule active

    1 trial

  22. Placebo Ocrevus, DIPHENHYDRAMINE HYDROCHLORIDE, METHYLPREDNISOLONE , METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE, Ocrevus 300 mg concentrate for solution for infusion, METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE, Dormutil N, Ocrevus 300 mg concentrate for solution for infusion

    Roche Registration Limited

    Primary progressive multiple sclerosis (PPMS)

    phase 3 small molecule active

    1 trial

  23. Placebo Trontinemab, Amyvid 800 MBq/mL solution for injection, VIZAMYL 400 MBq/mL solution for injection, Amyvid 1900 MBq/mL solution for injection, Amyvid 1900 MBq/mL solution for injection, Amyvid 800 MBq/mL solution for injection, Neuraceq 300 MBq/mL solution for injection, Trontinemab, [18F]MK-6240

    Roche Registration Limited

    Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD)

    phase 3 small molecule active

    1 trial

  24. Placebo tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion, Tiragolumab

    Roche Registration Limited

    Small cell lung cancer (SCLC)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources